Takeda
Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study
Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks
Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition
Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline
Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B
Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments
Takeda Expands De Novo Protein Research with Second AI-Driven Collaboration with Nabla Bio
Takeda; Nabla Bio; de novo protein design; AI drug discovery; Joint Atomic Model (JAM); multi-year collaboration; protein therapeutics; antibody design; biopharmaceutical innovation
Takeda to Cut 137 Staffers After Exiting Cell Therapy Research
Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up
Curtain Closes on Takeda’s Cell Therapy Efforts
Takeda; cell therapy; research discontinuation; impairment loss; gamma delta T-cell; strategic shift; biopharmaceuticals
Takeda and Alkermes Detail Strong Clinical Results for Orexin Drugs in Narcolepsy – Head-to-Head Race Accelerates
Takeda; Alkermes; orexin agonists; narcolepsy; oveporexton; alixorexton; clinical trials; Phase 3; excessive daytime sleepiness; cataplexy; maintenance of wakefulness test (MWT)
Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market
Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care
Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings
Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results
FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE
Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection